Gut microbiome in multiple sclerosis-related cognitive impairment

Ghadiri, Fereshteh; Ebadi, Zahra; Asadollahzadeh, Elnaz; Moghadasi, Abdorreza Naser

doi:10.1016/j.msard.2022.104165

Cited by 4 publications

(4 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modifications of the compositions of the gut microbiota have been identified in numerous pathologies and the different potential mechanisms of action have been described in a significant number of narrative reviews mostly focusing on Alzheimer's disease (AD) [11][12][13][14][15][16], Parkinson's disease (PD) [17][18][19][20][21][22][23], and multiple sclerosis (MS) [24][25][26][27]. Changes in the gut microbiota have also been found in stroke [28,29] and amyotrophic lateral sclerosis (ALS) [30,31].…”

Section: Introductionmentioning

confidence: 99%

What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review

Bonnechère

Amin

Duijn

2022

IJMS

View full text Add to dashboard Cite

There is a growing body of evidence highlighting there are significant changes in the gut microbiota composition and relative abundance in various neurological disorders. We performed a systematic review of the different microbiota altered in a wide range of neurological disorders (Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis, and stroke). Fifty-two studies were included representing 5496 patients. At the genus level, the most frequently involved microbiota are Akkermansia, Faecalibacterium, and Prevotella. The overlap between the pathologies was strongest for MS and PD, sharing eight genera (Akkermansia, Butyricicoccus, Bifidobacterium, Coprococcus, Dorea, Faecalibacterium, Parabacteroides, and Prevotella) and PD and stroke, sharing six genera (Enterococcus, Faecalibacterium, Lactobacillus, Parabacteroides, Prevotella, and Roseburia). The identification signatures overlapping for AD, PD, and MS raise the question of whether these reflect a common etiology or rather common consequence of these diseases. The interpretation is hampered by the low number and low power for AD, ALS, and stroke with ample opportunity for false positive and false negative findings.

show abstract

Section: Introductionmentioning

confidence: 99%

What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review

Bonnechère

Amin

Duijn

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Table 1 summarizes the major risk factors associated with cognitive impairment in MS, highlighting possible underlying pathophysiological and relevant references published in the last ten years. Diet Gut-brain axis Renin-angiotensin-aldosterone system [41][42][43][44] Lack of physical exercise To be determined [45,46] Smoking Increased plaque load Reduced gray matter fraction [47][48][49][50] Vitamin D deficiency…”

Section: Major Risk Factors For Cognitive Impairment In Ms Patientsmentioning

confidence: 99%

“…Before searching for a specific diet to improve cognitive impairment in MS patients, researchers should focus on understanding the MS-relevant molecular pathways that nutrients could modulate. In this regard, the gut-brain axis was explored in greater detail, with indirect research suggesting that dietary intervention at that level might benefit the cognitive deficit of MS [44]. Depending on the type of diet, the macro and micronutrients included alter the gut microbiome, which has a relevant impact on the local and systemic inflammatory status and consequences at the CNS level.…”

Section: Lifestyle Risk Factorsmentioning

confidence: 99%

Risk Factors for Cognitive Impairment in Multiple Sclerosis Patients

Schreiner,

Mihoc,

Grigore

et al. 2024

Sclerosis

View full text Add to dashboard Cite

Cognitive impairment is one of the most significant burdens among the many neurological complaints in multiple sclerosis patients. Cognitive deficits negatively impact these patients’ quality of life, leading to partial or total loss of several mental functions, such as learning, memory, perception, or problem-solving. While the precise mechanisms involved in the onset and evolution of cognitive decline remain unknown, several risk factors have been associated with intellectual disability. With increasing data on this topic in recent years, the main aim of this review is to summarize the most relevant risk factors correlated with cognitive impairment in multiple sclerosis patients. Firstly, the authors demonstrate the importance of mental disability based on epidemiological data from multiple sclerosis patient cohorts. Subsequently, the intensely debated major risk factors for cognitive decline are discussed, with brief insights into the pathophysiology and possible underlying mechanisms. Finally, the authors describe the impact of medication on cognitive impairment in multiple sclerosis patients, highlighting the main research directions for future studies.

show abstract

“…20 The collective microbiome is an important source of bidirectional host/symbiont signalling, and a healthy and balanced microbial composition may be altered by factors including environment, physiology, lifestyle and pathology. 21 22 Comorbid microbial dysbiosis and altered cognition are associated with poor diet and obesity, [23][24][25] stroke and Alzheimer's disease, 26 mild cognitive impairment, 27 dementia, 28 brain injury, 29 multiple sclerosis, 30 Lyme disease 4 and postacute sequelae of SARS-CoV-2. 10 Other diseases marked directly by intestinal difficulties and dysbiotic microbiome have also documented cognitive components including coeliac disease, 31 Crohn's disease, 32 Gulf War Syndrome 33 and inflammatory bowel disease.…”

Section: Open Accessmentioning

confidence: 99%

What is the association between the microbiome and cognition? An umbrella review protocol

Goldenberg,

Wright,

Batson

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionCognitive impairment is reported in a variety of clinical conditions including Alzheimer’s disease, Parkinson’s and ‘long-COVID’. Interestingly, many of these clinical conditions are also associated with microbial dysbiosis. This comanifestation of cognitive and microbiome findings in seemingly unrelated maladies suggests that they could share a common mechanism and potentially presents a treatment target. Although a rapidly growing body of literature has documented this comorbid presentation within specific conditions, an overview highlighting potential parallels across healthy and clinical populations is lacking. The objective of this umbrella review, therefore, is to summarise and synthesise the findings of these systematic reviews.Methods and analysisOn 2 April 2023, we searched MEDLINE (Pubmed), Embase (Ovid), the Web of Science (Core Collection), the Cochrane Library of Systematic Reviews and Epistemonikos as well as grey literature sources, for systematic reviews on clinical conditions and interventions where cognitive and microbiome outcomes were coreported. An updated search will be conducted before completion of the project if the search-to-publication date is >1 year old. Screening, data abstraction and quality assessment (AMSTAR 2, A MeaSurement Tool to Assess systematic Reviews) will be conducted independently and in duplicate, with disagreements resolved by consensus. Evidence certainty statements for each review’s conclusions (eg, Grading of Recommendations Assessment, Development and Evaluation (GRADE)) will be extracted or constructed de novo. A narrative synthesis will be conducted and delineated by the review question. Primary study overlap will be visualised using a citation matrix as well as calculated using the corrected covered area method.Ethics and disseminationNo participant-identifying information will be used in this review. No ethics approval was required due to our study methodology. Our findings will be presented at national and international conferences and disseminated via social media and press releases. We will recruit at least one person living with cognitive impairment to collaborate on writing the plain language summary for the review.PROSPERO registration numberCRD42023412903

show abstract

Gut microbiome in multiple sclerosis-related cognitive impairment

Cited by 4 publications

References 85 publications

What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review

What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review

Risk Factors for Cognitive Impairment in Multiple Sclerosis Patients

What is the association between the microbiome and cognition? An umbrella review protocol

Contact Info

Product

Resources

About